Skip to main content
Selvita S.A. logo

Selvita S.A. — Investor Relations & Filings

Ticker · SLV ISIN · PLSLVCR00029 LEI · 25940057WQ9YP5MOQF28 WAR Professional, scientific and technical activities
Open in API
Filings indexed 1,179 across all filing types
Latest filing 2023-01-25 Report Publication Anno…
Country PL Poland
Listing WAR SLV

About Selvita S.A.

https://selvita.com/

Selvita S.A. is a preclinical contract research organization (CRO) providing integrated services for the pharmaceutical and biotechnology sectors. The company offers comprehensive solutions across the drug discovery and development continuum, from target validation to preclinical candidate nomination. Core drug discovery capabilities include medicinal chemistry, pharmacology, DMPK, and protein sciences, supporting a wide range of modalities such as small molecules, antibodies, and protein degraders. For drug development, Selvita provides analytical support for small and large molecules, formulation, microbiology services, and manufacturing for clinical trials. The company operates under GMP and GLP quality standards, offering flexible engagement models that range from standalone studies to fully integrated programs.

Recent filings

Filing Released Lang Actions
Terminy przekazywania raportów okresowych w 2023 roku / Publication dates for periodic reports in 2023 - Content (EN)
Report Publication Announcement Classification · 100% confidence The document explicitly states that the Management Board of Selvita S.A. is announcing the publication dates for its periodic reports (annual, quarterly, semi-annual) for the year 2023. It cites regulatory requirements (§ 80.1 of the Regulation of the Minister of Finance). This document is not the report itself, but an announcement about *when* the reports will be released. This fits the definition of a Report Publication Announcement (RPA). The document length is very short (1393 chars), supporting the RPA classification over the full report classification (like 10-K or IR).
2023-01-25 English
Terminy przekazywania raportów okresowych w 2023 roku / Publication dates for periodic reports in 2023 - Content (PL)
Report Publication Announcement Classification · 100% confidence The document text, written in Polish, explicitly states that the Management Board ('Zarząd') of Selvita S.A. is announcing the publication dates ('terminy publikacji raportów okresowych') for its periodic reports (annual, Q1, H1, Q3) for the year 2023, citing a specific Polish Ministry of Finance regulation. This document is not the report itself (like a 10-K or IR), but rather an announcement detailing *when* those reports will be released. According to Rule 2, when a document announces the publication of reports, it should be classified as a Report Publication Announcement (RPA). The document length (1344 chars) is very short, supporting this interpretation.
2023-01-25 Polish
Zmiana zasad konsolidacji Ardigen S.A. w ramach grupy kapitałowej Selvita S.A. od 2023 r. / Change of consolidation methods of Ardigen S.A. within Selvita S.A. capital group from 2023 - Content (EN)
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding structure involving Selvita S.A. and its subsidiary/associated company Ardigen S.A., triggered by a capital increase at Ryvu Therapeutics S.A. This change directly impacts Selvita's control over Ardigen, leading to a change in accounting consolidation method (from full consolidation to recognizing Ardigen as an associated company). This type of disclosure, which concerns significant changes in corporate structure, control, and the resulting impact on financial reporting/consolidation, is best classified as a significant corporate event disclosure. While it touches upon financial reporting implications, it is not a standard Earnings Release (ER) or Interim Report (IR). It is a specific notification about a change in corporate relationship and its accounting consequence. Given the options, this is a material corporate event disclosure. Since it is not explicitly about M&A (TAR), Director's Dealing (DIRS), or a general regulatory filing (RNS), and it details a change in control affecting consolidation, it falls under a significant corporate update. However, looking closely at the definitions, it is a notification of a change in corporate structure and control, which often accompanies financing or major structural changes. Since the core event is the loss of control leading to a change in accounting treatment, and it is not a standard financial report, it is most closely aligned with a significant corporate event disclosure. Given the available codes, and since it is a specific, material announcement that isn't covered by the more specific financial report codes, it fits best as a Regulatory Filing (RNS) if no better fit exists, or potentially a Capital/Financing Update (CAP) if the initial trigger (Ryvu's capital increase) is the focus. However, the substance is the loss of control and change in consolidation. This is a material event disclosure. As it is a specific, non-standard disclosure about corporate structure and control, RNS is the most appropriate fallback for significant, non-standard corporate news not covered elsewhere. The document length is moderate, suggesting it is the primary report, not just an announcement of one.
2023-01-18 English
Zmiana zasad konsolidacji Ardigen S.A. w ramach grupy kapitałowej Selvita S.A. od 2023 r. / Change of consolidation methods of Ardigen S.A. within Selvita S.A. capital group from 2023 - Content (PL)
Major Shareholding Notification Classification · 99% confidence The document is a formal notification from the Management Board ('Zarząd') of Selvita S.A. regarding a change in its ownership structure and control over another company, Ryvu Therapeutics S.A., which subsequently impacted its control over a subsidiary, Ardigen S.A. Specifically, it details the loss of voting rights thresholds leading to the cessation of full consolidation of Ardigen's financial results starting in 2023, classifying Ardigen as an associate instead. This type of announcement, detailing significant corporate events, changes in control, and the resulting impact on financial reporting (consolidation), is characteristic of a major corporate disclosure. Since it is not a full annual report (10-K), an earnings release (ER), or a specific transaction announcement (like M&A or share repurchase), it falls best under the category of a general regulatory filing or a significant corporate event disclosure. Given the detailed nature of the change in control and consolidation policy, it is a significant regulatory disclosure, best categorized as 'Regulatory Filings' (RNS) as a catch-all for important, non-standard disclosures, or potentially related to 'Management Reports' (MDA) due to the explanation of financial impact, but RNS is safer for non-standard disclosures. However, since it directly addresses the change in the relationship between entities and the resulting accounting treatment (consolidation), it is a critical piece of corporate governance/financial structure information. Given the options, and that it is a formal notification of a change in control impacting financial reporting, 'Regulatory Filings' (RNS) is the most appropriate general category for such a specific, non-standard disclosure.
2023-01-18 Polish
Korekta raportu bieżącego nr 42/2022 - Content (EN)
Regulatory Filings Classification · 95% confidence The document is a correction to a previous current report (No. 42/2022) issued by the Management Board of Selvita S.A. It announces the receipt of a significant 'statement of work' (contract) by a subsidiary from a major pharmaceutical client. This announcement details the value, scope (drug discovery services), and strategic importance of the contract. This type of announcement, concerning a significant business contract or transaction that is not explicitly a financing event (CAP), share transaction (POS/SHA), or management change (MANG), falls best under the general category of Regulatory Filings (RNS) as a specific regulatory disclosure, or potentially a general business update. Since it is a specific disclosure about a significant business agreement, and RNS is the general regulatory fallback, RNS is the most appropriate classification for this type of ad-hoc regulatory disclosure that doesn't fit the other specific categories like DIV, DIRS, or M&A (TAR). The document is short and is an announcement of a business event, not a comprehensive report.
2022-12-23 English
Korekta raportu bieżącego nr 42/2022 - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a current report (raport bieżący) from Selvita S.A. in Polish. It explicitly states that it is a 'korekty oczywistej omyłki pisarskiej' (correction of an obvious typographical error) contained in a previous report (ESPI nr 42/2022). The content details the receipt of a significant contract ('Zlecenie') by a subsidiary, including its value, scope (drug discovery services), and duration. This type of announcement, detailing a significant business contract or order, does not fit neatly into the specific categories like 10-K, ER, or DIV. It is a material event disclosure. Since it is a specific regulatory disclosure about a business event (a large contract) and not a general announcement about publishing a report (RPA) or a general fallback (RNS), I must check the definitions. None of the definitions perfectly match 'Significant Contract Award'. However, given the nature of the content (a material business event disclosure that is not financial results, management change, or capital activity), it falls closest to a general regulatory filing or a specific business update. Since there is no specific code for 'Contract Award', and it is a formal, material disclosure, the most appropriate general category for non-standard, material regulatory announcements is 'Regulatory Filings' (RNS), as it is a specific type of current report that doesn't fit the other specialized codes. The document length is short (1712 chars), but it contains the full substance of the correction/update, not just a notice that a report is attached, thus avoiding the RPA classification.
2022-12-23 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.